Acknowledgement to reviewers of Cancer Drug Resistance in 2018
2018-02-18 09:24:22CancerDrugResistanceEditorialOffice
Cancer Drug Resistance 2018年4期
Cancer Drug Resistance Editorial Office
OAE Publishing Inc., Chaoyang District, Beijing 100027, China.
The editors of the Cancer Drug Resistance would like to take this opportunity to express their sincere gratitude to the reviewers and guest editors for assessing manuscripts in 2018 [Table 1].
Table 1. Names of reviewers and guest editors
DECLARATIONS
Authors' contributions
Writing and revision of the article and approved the final version: Cancer Drug Resistance Editorial Office
Availability of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
All authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
? The Author(s) 2018.
- Cancer Drug Resistance的其它文章
- Meeting Abstracts of the BACR conference:response and resistance in cancer therapy
- What really matters - response and resistance in cancer therapy
- Wilms' tumor gene (WT1) is strongly expressed in high-risk subsets of pediatric acute lymphoblastic leukemia
- Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
- Epigenetics, a key player of immunotherapy resistance
- Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials